Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

Viruses

Moheshwarnath Issur¹  Matthias Götte¹ 

[1] Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada; E-Mail:

关键词: Daclatasvir;    NS5A;    HCV;    resistance;    resistance barrier;    viral fitness;    DAA;   

DOI  :  10.3390/v6114227

来源: mdpi

【 摘 要 】

Direct-acting antivirals (DAAs) have significantly improved the treatment of infection with the hepatitis C virus. A promising class of novel antiviral agents targets the HCV NS5A protein. The high potency and broad genotypic coverage are favorable properties. NS5A inhibitors are currently assessed in advanced clinical trials in combination with viral polymerase inhibitors and/or viral protease inhibitors. However, the clinical use of NS5A inhibitors is also associated with new challenges. HCV variants with decreased susceptibility to these drugs can emerge and compromise therapy. In this review, we discuss resistance patterns in NS5A with focus prevalence and implications for inhibitor binding.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.